Placeholder image


Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.  

Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs.  

Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.  

Addex's lead drug candidate, dipraglurant (mGlu5 NAM), has successfully completed a Phase 2a POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID. In parallel, dipraglurant's therapeutic use in dystonia is being investigated in preclinical models 

Addex's second clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with our partner Janssen Pharmaceuticals, Inc., is scheduled to enter a Phase 2a proof of concept clinical study for the treatment of epilepsy.

 Preclinical programs include: 

  • GABAB PAM for addiction 
  • GABAB PAM for CMT1A 
  • mGlu7 NAM for PTSD 
  • mGlu2 NAM for mild neurocognitive disorders 
  • mGlu4 PAM for Parkinson’s disease  
  • mGlu3 PAM for neurodegenerative disorders 

Addex was founded in 2002, headquartered in Geneva, Switzerland and listed on the SIX Swiss Stock Exchange under the trading symbol ADXN since 2007, and on the NASDAQ exchange also under the trading symbol ADXN since 2020.  

Find out more about ouClinical and Pre-Clinical Pipeline.